Search

Protagonist Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

155.05 2.44

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

150.82

Max

155.38

Pagrindiniai rodikliai

By Trading Economics

Pajamos

159M

163M

Pardavimai

157M

213M

P/E

Sektoriaus vid.

140.187

57.002

Pelnas, tenkantis vienai akcijai

2.29

Pelno marža

76.285

Darbuotojai

141

EBITDA

162M

165M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+7.28% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.2B

9.7B

Ankstesnė atidarymo kaina

152.61

Ankstesnė uždarymo kaina

155.05

Naujienos nuotaikos

By Acuity

50%

50%

163 / 340 reitingas Healthcare

Protagonist Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-14 22:36; UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

2026-08-13 20:06; UTC

Correlated Moves
News
Social Media

Protagonist Therapeutics shares are lower amid insider selling concerns following CEO Dinesh V. Patel's recent stock transactions. The decline reflects broader sector trends.

2026-08-12 23:31; UTC

Social Media

Protagonist Therapeutics Inc gains after-market, reaching a high above Wednesday's close. Investor interest grows amid social media discussions on increasing positions.

2026-08-11 23:01; UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement amid earlier volatility and fluctuations.

2026-08-10 23:46; UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, with notable strength above the 20-day moving average and near the upper end of its one-month range.

2026-08-06 19:52; UTC

Social Media
News

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

2026-08-05 22:02; UTC

News

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

2026-08-04 21:03; UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

2026-08-03 19:36; UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

2026-07-31 19:36; UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

2026-07-30 21:02; UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

2026-07-29 19:43; UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

2026-07-28 21:01; UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

2026-07-27 20:02; UTC

Social Media

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

2026-07-22 19:42; UTC

News

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

2026-07-21 19:06; UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

2026-07-20 19:41; UTC

News
Social Media

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.

Akcijų palyginimas

Kainos pokytis

Protagonist Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

7.28% į viršų

12 mėnesių prognozė

Vidutinis 162.45 USD  7.28%

Aukščiausias 186 USD

Žemiausias 121 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Protagonist Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

11

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

163 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat